Zolmitriptan transdermal - PassPort Technologies
Latest Information Update: 03 Apr 2024
Price :
$50 *
At a glance
- Originator Passport Technologies
- Class Analgesics; Antimigraines; Indoles; Oxazolidinones; Small molecules; Tryptamines
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Migraine
Most Recent Events
- 29 Mar 2024 Adverse events data from a phase I trial in Migraine released by Passport Technologies
- 27 Feb 2024 Chemical structure addition request sent
- 27 Feb 2024 Zolmitriptan transdermal - PassPort Technologies is available for licensing as of 27 Feb 2024. https://passport-tech.com/ (PassPort Technologies pipeline, February 2024)